nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—Cytolytic hepatitis—Ramipril—type 1 diabetes mellitus	0.0384	0.0762	CcSEcCtD
Lenalidomide—Acute hepatic failure—Ramipril—type 1 diabetes mellitus	0.0296	0.0588	CcSEcCtD
Lenalidomide—CDH5—Cell-Cell communication—SKAP2—type 1 diabetes mellitus	0.022	0.0658	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—SIRPG—type 1 diabetes mellitus	0.022	0.0658	CbGpPWpGaD
Lenalidomide—TNFSF11—lymphoid tissue—type 1 diabetes mellitus	0.0186	0.137	CbGeAlD
Lenalidomide—Polyneuropathy—Ramipril—type 1 diabetes mellitus	0.0182	0.0362	CcSEcCtD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—VAV1—type 1 diabetes mellitus	0.018	0.0539	CbGpPWpGaD
Lenalidomide—CDH5—cardiovascular system—type 1 diabetes mellitus	0.0166	0.123	CbGeAlD
Lenalidomide—Pomalidomide—TNF—type 1 diabetes mellitus	0.0164	0.608	CrCbGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—VAV1—type 1 diabetes mellitus	0.0157	0.047	CbGpPWpGaD
Lenalidomide—CRBN—islet of Langerhans—type 1 diabetes mellitus	0.0146	0.108	CbGeAlD
Lenalidomide—CDH5—lymphoid tissue—type 1 diabetes mellitus	0.014	0.103	CbGeAlD
Lenalidomide—CRBN—retina—type 1 diabetes mellitus	0.0125	0.0923	CbGeAlD
Lenalidomide—Cerebral ischaemia—Ramipril—type 1 diabetes mellitus	0.0123	0.0244	CcSEcCtD
Lenalidomide—Transient ischaemic attack—Ramipril—type 1 diabetes mellitus	0.0118	0.0234	CcSEcCtD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—PTPN2—type 1 diabetes mellitus	0.0118	0.0352	CbGpPWpGaD
Lenalidomide—CRBN—nephron tubule—type 1 diabetes mellitus	0.0118	0.0869	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—CRP—type 1 diabetes mellitus	0.0113	0.0338	CbGpPWpGaD
Lenalidomide—Thalidomide—TNF—type 1 diabetes mellitus	0.0106	0.392	CrCbGaD
Lenalidomide—CRBN—pancreas—type 1 diabetes mellitus	0.0103	0.0758	CbGeAlD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—NOS3—type 1 diabetes mellitus	0.0095	0.0284	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—INS—type 1 diabetes mellitus	0.00929	0.0278	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—ITPR3—type 1 diabetes mellitus	0.00901	0.027	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—IGF1—type 1 diabetes mellitus	0.00898	0.0269	CbGpPWpGaD
Lenalidomide—CRBN—lymphoid tissue—type 1 diabetes mellitus	0.00888	0.0656	CbGeAlD
Lenalidomide—Bone marrow depression—Ramipril—type 1 diabetes mellitus	0.00879	0.0175	CcSEcCtD
Lenalidomide—Burning sensation—Ramipril—type 1 diabetes mellitus	0.00854	0.017	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—ITPR3—type 1 diabetes mellitus	0.00851	0.0254	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—TYK2—type 1 diabetes mellitus	0.00844	0.0252	CbGpPWpGaD
Lenalidomide—Myocardial ischaemia—Ramipril—type 1 diabetes mellitus	0.00738	0.0147	CcSEcCtD
Lenalidomide—Ageusia—Ramipril—type 1 diabetes mellitus	0.00733	0.0146	CcSEcCtD
Lenalidomide—Endocrine disorder—Ramipril—type 1 diabetes mellitus	0.00716	0.0142	CcSEcCtD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—HSD11B2—type 1 diabetes mellitus	0.00665	0.0199	CbGpPWpGaD
Lenalidomide—Hearing impaired—Ramipril—type 1 diabetes mellitus	0.00624	0.0124	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—VAV1—type 1 diabetes mellitus	0.00617	0.0184	CbGpPWpGaD
Lenalidomide—Hepatocellular injury—Ramipril—type 1 diabetes mellitus	0.00594	0.0118	CcSEcCtD
Lenalidomide—TNFSF11—IL6-mediated signaling events—STAT3—type 1 diabetes mellitus	0.00591	0.0177	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—VAV1—type 1 diabetes mellitus	0.00582	0.0174	CbGpPWpGaD
Lenalidomide—Neuropathy—Ramipril—type 1 diabetes mellitus	0.00557	0.0111	CcSEcCtD
Lenalidomide—Gynaecomastia—Ramipril—type 1 diabetes mellitus	0.00531	0.0106	CcSEcCtD
Lenalidomide—Sleep disorder—Ramipril—type 1 diabetes mellitus	0.00498	0.00989	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—FGF21—type 1 diabetes mellitus	0.00493	0.0147	CbGpPWpGaD
Lenalidomide—Gastroenteritis—Ramipril—type 1 diabetes mellitus	0.00486	0.00966	CcSEcCtD
Lenalidomide—Deafness—Ramipril—type 1 diabetes mellitus	0.00482	0.00957	CcSEcCtD
Lenalidomide—Hepatic failure—Ramipril—type 1 diabetes mellitus	0.00479	0.00953	CcSEcCtD
Lenalidomide—Haemolytic anaemia—Ramipril—type 1 diabetes mellitus	0.00477	0.00948	CcSEcCtD
Lenalidomide—Nasal congestion—Ramipril—type 1 diabetes mellitus	0.00473	0.0094	CcSEcCtD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—type 1 diabetes mellitus	0.00467	0.014	CbGpPWpGaD
Lenalidomide—Renal failure acute—Ramipril—type 1 diabetes mellitus	0.00467	0.00927	CcSEcCtD
Lenalidomide—Atrial fibrillation—Ramipril—type 1 diabetes mellitus	0.00455	0.00903	CcSEcCtD
Lenalidomide—Arthritis—Ramipril—type 1 diabetes mellitus	0.00443	0.00881	CcSEcCtD
Lenalidomide—Hypoglycaemia—Ramipril—type 1 diabetes mellitus	0.00442	0.00877	CcSEcCtD
Lenalidomide—Cardiac failure—Ramipril—type 1 diabetes mellitus	0.00442	0.00877	CcSEcCtD
Lenalidomide—Cerebrovascular accident—Ramipril—type 1 diabetes mellitus	0.0044	0.00874	CcSEcCtD
Lenalidomide—Hyponatraemia—Ramipril—type 1 diabetes mellitus	0.00433	0.0086	CcSEcCtD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NOS1—type 1 diabetes mellitus	0.00418	0.0125	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IL6—type 1 diabetes mellitus	0.00413	0.0123	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—IL6—type 1 diabetes mellitus	0.00406	0.0121	CbGpPWpGaD
Lenalidomide—Blood creatinine increased—Ramipril—type 1 diabetes mellitus	0.00404	0.00802	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—DDIT3—type 1 diabetes mellitus	0.00401	0.012	CbGpPWpGaD
Lenalidomide—Liver function test abnormal—Ramipril—type 1 diabetes mellitus	0.00398	0.0079	CcSEcCtD
Lenalidomide—PTGS2—islet of Langerhans—type 1 diabetes mellitus	0.00398	0.0294	CbGeAlD
Lenalidomide—Abdominal pain upper—Ramipril—type 1 diabetes mellitus	0.00394	0.00782	CcSEcCtD
Lenalidomide—Breast disorder—Ramipril—type 1 diabetes mellitus	0.00389	0.00774	CcSEcCtD
Lenalidomide—Cramp muscle—Ramipril—type 1 diabetes mellitus	0.00388	0.00771	CcSEcCtD
Lenalidomide—Toxic epidermal necrolysis—Ramipril—type 1 diabetes mellitus	0.00388	0.00771	CcSEcCtD
Lenalidomide—Gastritis—Ramipril—type 1 diabetes mellitus	0.00381	0.00758	CcSEcCtD
Lenalidomide—Asthma—Ramipril—type 1 diabetes mellitus	0.00372	0.0074	CcSEcCtD
Lenalidomide—Influenza—Ramipril—type 1 diabetes mellitus	0.00372	0.0074	CcSEcCtD
Lenalidomide—Dysphagia—Ramipril—type 1 diabetes mellitus	0.00372	0.0074	CcSEcCtD
Lenalidomide—Pancreatitis—Ramipril—type 1 diabetes mellitus	0.00365	0.00725	CcSEcCtD
Lenalidomide—Angina pectoris—Ramipril—type 1 diabetes mellitus	0.00363	0.00721	CcSEcCtD
Lenalidomide—Sweating increased—Ramipril—type 1 diabetes mellitus	0.00363	0.00721	CcSEcCtD
Lenalidomide—Bronchitis—Ramipril—type 1 diabetes mellitus	0.00358	0.00712	CcSEcCtD
Lenalidomide—Abdominal discomfort—Ramipril—type 1 diabetes mellitus	0.00357	0.00709	CcSEcCtD
Lenalidomide—Pancytopenia—Ramipril—type 1 diabetes mellitus	0.00354	0.00703	CcSEcCtD
Lenalidomide—Neutropenia—Ramipril—type 1 diabetes mellitus	0.00348	0.00692	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Ramipril—type 1 diabetes mellitus	0.00346	0.00688	CcSEcCtD
Lenalidomide—Erectile dysfunction—Ramipril—type 1 diabetes mellitus	0.00343	0.00681	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Ramipril—type 1 diabetes mellitus	0.0034	0.00675	CcSEcCtD
Lenalidomide—Weight increased—Ramipril—type 1 diabetes mellitus	0.00339	0.00673	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—TYK2—type 1 diabetes mellitus	0.00331	0.00991	CbGpPWpGaD
Lenalidomide—Stevens-Johnson syndrome—Ramipril—type 1 diabetes mellitus	0.00329	0.00654	CcSEcCtD
Lenalidomide—Acute coronary syndrome—Ramipril—type 1 diabetes mellitus	0.00327	0.0065	CcSEcCtD
Lenalidomide—Renal failure—Ramipril—type 1 diabetes mellitus	0.00326	0.00649	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Ramipril—type 1 diabetes mellitus	0.00325	0.00647	CcSEcCtD
Lenalidomide—Myocardial infarction—Ramipril—type 1 diabetes mellitus	0.00325	0.00647	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NOS3—type 1 diabetes mellitus	0.00325	0.00972	CbGpPWpGaD
Lenalidomide—Stomatitis—Ramipril—type 1 diabetes mellitus	0.00324	0.00643	CcSEcCtD
Lenalidomide—Urinary tract infection—Ramipril—type 1 diabetes mellitus	0.00323	0.00641	CcSEcCtD
Lenalidomide—Conjunctivitis—Ramipril—type 1 diabetes mellitus	0.00323	0.00641	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—AIF1—type 1 diabetes mellitus	0.00321	0.0096	CbGpPWpGaD
Lenalidomide—Sweating—Ramipril—type 1 diabetes mellitus	0.00318	0.00632	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Ramipril—type 1 diabetes mellitus	0.00314	0.00624	CcSEcCtD
Lenalidomide—Epistaxis—Ramipril—type 1 diabetes mellitus	0.00313	0.00622	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—TYK2—type 1 diabetes mellitus	0.00313	0.00935	CbGpPWpGaD
Lenalidomide—Sinusitis—Ramipril—type 1 diabetes mellitus	0.00312	0.00619	CcSEcCtD
Lenalidomide—Agranulocytosis—Ramipril—type 1 diabetes mellitus	0.0031	0.00616	CcSEcCtD
Lenalidomide—ABCB1—ABC-family proteins mediated transport—ABCC8—type 1 diabetes mellitus	0.00309	0.00924	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—NOS3—type 1 diabetes mellitus	0.00307	0.00918	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CBLB—type 1 diabetes mellitus	0.00302	0.00902	CbGpPWpGaD
Lenalidomide—Hepatitis—Ramipril—type 1 diabetes mellitus	0.00298	0.00592	CcSEcCtD
Lenalidomide—Oedema peripheral—Ramipril—type 1 diabetes mellitus	0.00294	0.00583	CcSEcCtD
Lenalidomide—Connective tissue disorder—Ramipril—type 1 diabetes mellitus	0.00293	0.00582	CcSEcCtD
Lenalidomide—PTGS2—cardiovascular system—type 1 diabetes mellitus	0.00288	0.0212	CbGeAlD
Lenalidomide—Visual impairment—Ramipril—type 1 diabetes mellitus	0.00287	0.00571	CcSEcCtD
Lenalidomide—Erythema multiforme—Ramipril—type 1 diabetes mellitus	0.00282	0.0056	CcSEcCtD
Lenalidomide—PTGS2—kidney—type 1 diabetes mellitus	0.00281	0.0208	CbGeAlD
Lenalidomide—PTGS2—pancreas—type 1 diabetes mellitus	0.0028	0.0207	CbGeAlD
Lenalidomide—Tinnitus—Ramipril—type 1 diabetes mellitus	0.00278	0.00552	CcSEcCtD
Lenalidomide—Flushing—Ramipril—type 1 diabetes mellitus	0.00277	0.0055	CcSEcCtD
Lenalidomide—Immune system disorder—Ramipril—type 1 diabetes mellitus	0.00269	0.00535	CcSEcCtD
Lenalidomide—Mediastinal disorder—Ramipril—type 1 diabetes mellitus	0.00269	0.00534	CcSEcCtD
Lenalidomide—Arrhythmia—Ramipril—type 1 diabetes mellitus	0.00266	0.00529	CcSEcCtD
Lenalidomide—Alopecia—Ramipril—type 1 diabetes mellitus	0.00263	0.00523	CcSEcCtD
Lenalidomide—Mental disorder—Ramipril—type 1 diabetes mellitus	0.00261	0.00519	CcSEcCtD
Lenalidomide—Erythema—Ramipril—type 1 diabetes mellitus	0.00259	0.00516	CcSEcCtD
Lenalidomide—Malnutrition—Ramipril—type 1 diabetes mellitus	0.00259	0.00516	CcSEcCtD
Lenalidomide—Tension—Ramipril—type 1 diabetes mellitus	0.00255	0.00506	CcSEcCtD
Lenalidomide—Dysgeusia—Ramipril—type 1 diabetes mellitus	0.00254	0.00505	CcSEcCtD
Lenalidomide—Nervousness—Ramipril—type 1 diabetes mellitus	0.00252	0.00501	CcSEcCtD
Lenalidomide—Muscle spasms—Ramipril—type 1 diabetes mellitus	0.00249	0.00496	CcSEcCtD
Lenalidomide—ABCB1—islet of Langerhans—type 1 diabetes mellitus	0.00246	0.0182	CbGeAlD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—type 1 diabetes mellitus	0.00244	0.00731	CbGpPWpGaD
Lenalidomide—Tremor—Ramipril—type 1 diabetes mellitus	0.00243	0.00483	CcSEcCtD
Lenalidomide—PTGS2—lymphoid tissue—type 1 diabetes mellitus	0.00242	0.0179	CbGeAlD
Lenalidomide—Ill-defined disorder—Ramipril—type 1 diabetes mellitus	0.00241	0.00478	CcSEcCtD
Lenalidomide—Agitation—Ramipril—type 1 diabetes mellitus	0.00238	0.00474	CcSEcCtD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CRP—type 1 diabetes mellitus	0.00238	0.00713	CbGpPWpGaD
Lenalidomide—Angioedema—Ramipril—type 1 diabetes mellitus	0.00237	0.00471	CcSEcCtD
Lenalidomide—Malaise—Ramipril—type 1 diabetes mellitus	0.00234	0.00465	CcSEcCtD
Lenalidomide—Vertigo—Ramipril—type 1 diabetes mellitus	0.00233	0.00463	CcSEcCtD
Lenalidomide—Syncope—Ramipril—type 1 diabetes mellitus	0.00233	0.00462	CcSEcCtD
Lenalidomide—Leukopenia—Ramipril—type 1 diabetes mellitus	0.00232	0.00461	CcSEcCtD
Lenalidomide—Palpitations—Ramipril—type 1 diabetes mellitus	0.00229	0.00456	CcSEcCtD
Lenalidomide—Loss of consciousness—Ramipril—type 1 diabetes mellitus	0.00228	0.00453	CcSEcCtD
Lenalidomide—Cough—Ramipril—type 1 diabetes mellitus	0.00226	0.0045	CcSEcCtD
Lenalidomide—ABCB1—Drug Induction of Bile Acid Pathway—VDR—type 1 diabetes mellitus	0.00226	0.00676	CbGpPWpGaD
Lenalidomide—Myalgia—Ramipril—type 1 diabetes mellitus	0.00221	0.00439	CcSEcCtD
Lenalidomide—Arthralgia—Ramipril—type 1 diabetes mellitus	0.00221	0.00439	CcSEcCtD
Lenalidomide—Chest pain—Ramipril—type 1 diabetes mellitus	0.00221	0.00439	CcSEcCtD
Lenalidomide—Anxiety—Ramipril—type 1 diabetes mellitus	0.0022	0.00437	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 1 diabetes mellitus	0.00219	0.00436	CcSEcCtD
Lenalidomide—Discomfort—Ramipril—type 1 diabetes mellitus	0.00218	0.00434	CcSEcCtD
Lenalidomide—Dry mouth—Ramipril—type 1 diabetes mellitus	0.00216	0.00429	CcSEcCtD
Lenalidomide—Confusional state—Ramipril—type 1 diabetes mellitus	0.00214	0.00424	CcSEcCtD
Lenalidomide—Oedema—Ramipril—type 1 diabetes mellitus	0.00212	0.00421	CcSEcCtD
Lenalidomide—ABCB1—retina—type 1 diabetes mellitus	0.0021	0.0155	CbGeAlD
Lenalidomide—Shock—Ramipril—type 1 diabetes mellitus	0.00208	0.00414	CcSEcCtD
Lenalidomide—Nervous system disorder—Ramipril—type 1 diabetes mellitus	0.00208	0.00413	CcSEcCtD
Lenalidomide—Thrombocytopenia—Ramipril—type 1 diabetes mellitus	0.00207	0.00412	CcSEcCtD
Lenalidomide—Tachycardia—Ramipril—type 1 diabetes mellitus	0.00207	0.00411	CcSEcCtD
Lenalidomide—Skin disorder—Ramipril—type 1 diabetes mellitus	0.00206	0.00409	CcSEcCtD
Lenalidomide—Hyperhidrosis—Ramipril—type 1 diabetes mellitus	0.00205	0.00407	CcSEcCtD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—type 1 diabetes mellitus	0.00202	0.00605	CbGpPWpGaD
Lenalidomide—Anorexia—Ramipril—type 1 diabetes mellitus	0.00202	0.00401	CcSEcCtD
Lenalidomide—ABCB1—nephron tubule—type 1 diabetes mellitus	0.00198	0.0146	CbGeAlD
Lenalidomide—Hypotension—Ramipril—type 1 diabetes mellitus	0.00198	0.00393	CcSEcCtD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—type 1 diabetes mellitus	0.00197	0.00588	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Ramipril—type 1 diabetes mellitus	0.00193	0.00383	CcSEcCtD
Lenalidomide—Insomnia—Ramipril—type 1 diabetes mellitus	0.00192	0.00381	CcSEcCtD
Lenalidomide—Paraesthesia—Ramipril—type 1 diabetes mellitus	0.0019	0.00378	CcSEcCtD
Lenalidomide—Dyspnoea—Ramipril—type 1 diabetes mellitus	0.00189	0.00375	CcSEcCtD
Lenalidomide—Somnolence—Ramipril—type 1 diabetes mellitus	0.00188	0.00374	CcSEcCtD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—FASLG—type 1 diabetes mellitus	0.00188	0.00562	CbGpPWpGaD
Lenalidomide—Dyspepsia—Ramipril—type 1 diabetes mellitus	0.00186	0.0037	CcSEcCtD
Lenalidomide—Decreased appetite—Ramipril—type 1 diabetes mellitus	0.00184	0.00366	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Ramipril—type 1 diabetes mellitus	0.00183	0.00363	CcSEcCtD
Lenalidomide—Fatigue—Ramipril—type 1 diabetes mellitus	0.00183	0.00363	CcSEcCtD
Lenalidomide—Constipation—Ramipril—type 1 diabetes mellitus	0.00181	0.0036	CcSEcCtD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—type 1 diabetes mellitus	0.0018	0.00539	CbGpPWpGaD
Lenalidomide—ABCB1—cardiovascular system—type 1 diabetes mellitus	0.00178	0.0131	CbGeAlD
Lenalidomide—Feeling abnormal—Ramipril—type 1 diabetes mellitus	0.00175	0.00347	CcSEcCtD
Lenalidomide—ABCB1—kidney—type 1 diabetes mellitus	0.00174	0.0129	CbGeAlD
Lenalidomide—Gastrointestinal pain—Ramipril—type 1 diabetes mellitus	0.00173	0.00344	CcSEcCtD
Lenalidomide—ABCB1—pancreas—type 1 diabetes mellitus	0.00173	0.0128	CbGeAlD
Lenalidomide—Urticaria—Ramipril—type 1 diabetes mellitus	0.00168	0.00334	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—type 1 diabetes mellitus	0.00168	0.00503	CbGpPWpGaD
Lenalidomide—Body temperature increased—Ramipril—type 1 diabetes mellitus	0.00167	0.00333	CcSEcCtD
Lenalidomide—Abdominal pain—Ramipril—type 1 diabetes mellitus	0.00167	0.00333	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6—type 1 diabetes mellitus	0.00162	0.00485	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PRKCQ—type 1 diabetes mellitus	0.00157	0.00471	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Ramipril—type 1 diabetes mellitus	0.00156	0.0031	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—IL6—type 1 diabetes mellitus	0.00153	0.00457	CbGpPWpGaD
Lenalidomide—Asthenia—Ramipril—type 1 diabetes mellitus	0.00152	0.00302	CcSEcCtD
Lenalidomide—Pruritus—Ramipril—type 1 diabetes mellitus	0.0015	0.00298	CcSEcCtD
Lenalidomide—ABCB1—lymphoid tissue—type 1 diabetes mellitus	0.00149	0.011	CbGeAlD
Lenalidomide—Diarrhoea—Ramipril—type 1 diabetes mellitus	0.00145	0.00288	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP12—type 1 diabetes mellitus	0.00141	0.00421	CbGpPWpGaD
Lenalidomide—Dizziness—Ramipril—type 1 diabetes mellitus	0.0014	0.00278	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL1R1—type 1 diabetes mellitus	0.0014	0.00418	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—IGFBP1—type 1 diabetes mellitus	0.00137	0.00411	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—PRF1—type 1 diabetes mellitus	0.00136	0.00408	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—E2F1—type 1 diabetes mellitus	0.00135	0.00405	CbGpPWpGaD
Lenalidomide—Vomiting—Ramipril—type 1 diabetes mellitus	0.00135	0.00268	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—CP—type 1 diabetes mellitus	0.00134	0.00401	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—HBA1—type 1 diabetes mellitus	0.00134	0.004	CbGpPWpGaD
Lenalidomide—Rash—Ramipril—type 1 diabetes mellitus	0.00134	0.00265	CcSEcCtD
Lenalidomide—Dermatitis—Ramipril—type 1 diabetes mellitus	0.00133	0.00265	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—type 1 diabetes mellitus	0.00133	0.00399	CbGpPWpGaD
Lenalidomide—Headache—Ramipril—type 1 diabetes mellitus	0.00133	0.00264	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—type 1 diabetes mellitus	0.00131	0.00391	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—type 1 diabetes mellitus	0.0013	0.00388	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—type 1 diabetes mellitus	0.00127	0.00381	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—E2F1—type 1 diabetes mellitus	0.00127	0.00378	CbGpPWpGaD
Lenalidomide—Nausea—Ramipril—type 1 diabetes mellitus	0.00126	0.0025	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—type 1 diabetes mellitus	0.00122	0.00364	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—FOXP3—type 1 diabetes mellitus	0.0012	0.00359	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—type 1 diabetes mellitus	0.00119	0.00356	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—LGALS3—type 1 diabetes mellitus	0.00118	0.00352	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—type 1 diabetes mellitus	0.00117	0.00349	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—TNF—type 1 diabetes mellitus	0.00108	0.00323	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—type 1 diabetes mellitus	0.00106	0.00316	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GAL—type 1 diabetes mellitus	0.00106	0.00316	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL20—type 1 diabetes mellitus	0.00104	0.00312	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL11—type 1 diabetes mellitus	0.00104	0.00312	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—type 1 diabetes mellitus	0.00103	0.00309	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP12—type 1 diabetes mellitus	0.000997	0.00298	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CHRM2—type 1 diabetes mellitus	0.000982	0.00294	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IL1R1—type 1 diabetes mellitus	0.00095	0.00284	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ITPR3—type 1 diabetes mellitus	0.000882	0.00264	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CAT—type 1 diabetes mellitus	0.000881	0.00264	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DPB1—type 1 diabetes mellitus	0.000872	0.00261	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—IL6—type 1 diabetes mellitus	0.000871	0.00261	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-E—type 1 diabetes mellitus	0.000858	0.00257	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—NOS1—type 1 diabetes mellitus	0.000846	0.00253	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SOD2—type 1 diabetes mellitus	0.000835	0.0025	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SH2B3—type 1 diabetes mellitus	0.00083	0.00248	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CTLA4—type 1 diabetes mellitus	0.000827	0.00247	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APOC3—type 1 diabetes mellitus	0.000825	0.00247	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IAPP—type 1 diabetes mellitus	0.000825	0.00247	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—type 1 diabetes mellitus	0.000769	0.0023	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL10—type 1 diabetes mellitus	0.000767	0.00229	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DQA1—type 1 diabetes mellitus	0.000728	0.00218	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SST—type 1 diabetes mellitus	0.000724	0.00217	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ADRB1—type 1 diabetes mellitus	0.000721	0.00216	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IAPP—type 1 diabetes mellitus	0.000715	0.00214	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CRP—type 1 diabetes mellitus	0.000699	0.00209	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—type 1 diabetes mellitus	0.000684	0.00205	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—type 1 diabetes mellitus	0.000683	0.00204	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DQB1—type 1 diabetes mellitus	0.000681	0.00204	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IL1R1—type 1 diabetes mellitus	0.000673	0.00201	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD86—type 1 diabetes mellitus	0.000656	0.00196	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GCG—type 1 diabetes mellitus	0.000645	0.00193	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL10—type 1 diabetes mellitus	0.000643	0.00192	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD40LG—type 1 diabetes mellitus	0.000643	0.00192	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL4—type 1 diabetes mellitus	0.00064	0.00191	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—E2F1—type 1 diabetes mellitus	0.000637	0.0019	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL4—type 1 diabetes mellitus	0.000625	0.00187	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PRKCQ—type 1 diabetes mellitus	0.000621	0.00186	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC29A3—type 1 diabetes mellitus	0.000614	0.00184	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-B—type 1 diabetes mellitus	0.000611	0.00183	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VAV1—type 1 diabetes mellitus	0.000603	0.0018	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCL10—type 1 diabetes mellitus	0.000602	0.0018	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—FASLG—type 1 diabetes mellitus	0.000598	0.00179	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—INS—type 1 diabetes mellitus	0.000585	0.00175	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL2RA—type 1 diabetes mellitus	0.000573	0.00171	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—NOS2—type 1 diabetes mellitus	0.000569	0.0017	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-A—type 1 diabetes mellitus	0.000567	0.00169	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—type 1 diabetes mellitus	0.000559	0.00167	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IGF2—type 1 diabetes mellitus	0.000546	0.00163	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—ALB—type 1 diabetes mellitus	0.000536	0.0016	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—type 1 diabetes mellitus	0.000532	0.00159	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CD86—type 1 diabetes mellitus	0.000526	0.00157	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CDK4—type 1 diabetes mellitus	0.000519	0.00155	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DRB1—type 1 diabetes mellitus	0.000518	0.00155	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IAPP—type 1 diabetes mellitus	0.000507	0.00152	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—NOS2—type 1 diabetes mellitus	0.000504	0.00151	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—E2F1—type 1 diabetes mellitus	0.000499	0.00149	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—type 1 diabetes mellitus	0.000498	0.00149	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CD4—type 1 diabetes mellitus	0.00049	0.00147	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IFNG—type 1 diabetes mellitus	0.000489	0.00146	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD80—type 1 diabetes mellitus	0.000478	0.00143	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ERBB3—type 1 diabetes mellitus	0.000474	0.00142	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCR5—type 1 diabetes mellitus	0.000467	0.0014	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL2RA—type 1 diabetes mellitus	0.00046	0.00138	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL1B—type 1 diabetes mellitus	0.000436	0.00131	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—E2F1—type 1 diabetes mellitus	0.000433	0.0013	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—type 1 diabetes mellitus	0.000416	0.00124	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IFNG—type 1 diabetes mellitus	0.000387	0.00116	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CD80—type 1 diabetes mellitus	0.000384	0.00115	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IFNG—type 1 diabetes mellitus	0.000378	0.00113	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—G6PC2—type 1 diabetes mellitus	0.000372	0.00111	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—INS—type 1 diabetes mellitus	0.000363	0.00108	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—type 1 diabetes mellitus	0.000353	0.00106	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IGF1—type 1 diabetes mellitus	0.000351	0.00105	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL1B—type 1 diabetes mellitus	0.000345	0.00103	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CASP3—type 1 diabetes mellitus	0.000344	0.00103	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL2—type 1 diabetes mellitus	0.000344	0.00103	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL1B—type 1 diabetes mellitus	0.000337	0.00101	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CASP3—type 1 diabetes mellitus	0.000336	0.00101	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL2—type 1 diabetes mellitus	0.000336	0.001	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TYK2—type 1 diabetes mellitus	0.000324	0.000969	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ABCC8—type 1 diabetes mellitus	0.000323	0.000965	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOS3—type 1 diabetes mellitus	0.000318	0.000951	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—type 1 diabetes mellitus	0.000317	0.000947	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—E2F1—type 1 diabetes mellitus	0.000307	0.000918	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—type 1 diabetes mellitus	0.000304	0.00091	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOC3—type 1 diabetes mellitus	0.000299	0.000894	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—type 1 diabetes mellitus	0.000295	0.000882	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—G6PC2—type 1 diabetes mellitus	0.000294	0.000878	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CASP3—type 1 diabetes mellitus	0.00027	0.000808	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL2—type 1 diabetes mellitus	0.00027	0.000806	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—type 1 diabetes mellitus	0.000263	0.000786	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HBA2—type 1 diabetes mellitus	0.000262	0.000782	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—type 1 diabetes mellitus	0.000255	0.000764	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—type 1 diabetes mellitus	0.00025	0.000749	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—type 1 diabetes mellitus	0.00025	0.000749	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC18A2—type 1 diabetes mellitus	0.000247	0.000739	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—G6PC2—type 1 diabetes mellitus	0.000246	0.000735	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TNF—type 1 diabetes mellitus	0.000245	0.000732	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—type 1 diabetes mellitus	0.000234	0.000701	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—CP—type 1 diabetes mellitus	0.000227	0.00068	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—STAT3—type 1 diabetes mellitus	0.000227	0.000679	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC11A1—type 1 diabetes mellitus	0.000225	0.000674	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—type 1 diabetes mellitus	0.000216	0.000645	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCC8—type 1 diabetes mellitus	0.000213	0.000638	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EGFR—type 1 diabetes mellitus	0.000206	0.000617	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—type 1 diabetes mellitus	0.000202	0.000604	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HBA2—type 1 diabetes mellitus	0.000185	0.000555	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—type 1 diabetes mellitus	0.000179	0.000535	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SLC11A1—type 1 diabetes mellitus	0.000178	0.000532	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—G6PC2—type 1 diabetes mellitus	0.000174	0.000521	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—type 1 diabetes mellitus	0.00017	0.00051	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ITPR3—type 1 diabetes mellitus	0.00017	0.000508	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—KCNJ11—type 1 diabetes mellitus	0.000169	0.000504	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—type 1 diabetes mellitus	0.000166	0.000497	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IAPP—type 1 diabetes mellitus	0.000159	0.000475	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOC3—type 1 diabetes mellitus	0.000159	0.000475	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—type 1 diabetes mellitus	0.000158	0.000474	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—B2M—type 1 diabetes mellitus	0.000152	0.000456	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ABCC8—type 1 diabetes mellitus	0.000151	0.000452	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ITPR3—type 1 diabetes mellitus	0.000142	0.000425	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HBA1—type 1 diabetes mellitus	0.000134	0.0004	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOC3—type 1 diabetes mellitus	0.000133	0.000398	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTT1—type 1 diabetes mellitus	0.000131	0.000391	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS1—type 1 diabetes mellitus	0.000128	0.000382	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—type 1 diabetes mellitus	0.000127	0.000379	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—type 1 diabetes mellitus	0.000121	0.000361	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	0.00012	0.00036	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PRKCQ—type 1 diabetes mellitus	0.00012	0.000358	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—KCNJ11—type 1 diabetes mellitus	0.000119	0.000357	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—VAV1—type 1 diabetes mellitus	0.000116	0.000348	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GCG—type 1 diabetes mellitus	0.000104	0.000311	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD86—type 1 diabetes mellitus	0.000101	0.000303	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ITPR3—type 1 diabetes mellitus	0.000101	0.000302	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HBA1—type 1 diabetes mellitus	9.49e-05	0.000284	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOC3—type 1 diabetes mellitus	9.43e-05	0.000282	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTT1—type 1 diabetes mellitus	9.26e-05	0.000277	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB3—type 1 diabetes mellitus	9.14e-05	0.000273	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CCR5—type 1 diabetes mellitus	8.99e-05	0.000269	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CAT—type 1 diabetes mellitus	8.81e-05	0.000264	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HLA-A—type 1 diabetes mellitus	8.76e-05	0.000262	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ALB—type 1 diabetes mellitus	8.12e-05	0.000243	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS2—type 1 diabetes mellitus	7.62e-05	0.000228	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD80—type 1 diabetes mellitus	7.39e-05	0.000221	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GCG—type 1 diabetes mellitus	7.38e-05	0.000221	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—INS—type 1 diabetes mellitus	6.99e-05	0.000209	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CAT—type 1 diabetes mellitus	6.25e-05	0.000187	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TYK2—type 1 diabetes mellitus	6.24e-05	0.000187	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS3—type 1 diabetes mellitus	6.13e-05	0.000183	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—INS—type 1 diabetes mellitus	5.85e-05	0.000175	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD4—type 1 diabetes mellitus	5.64e-05	0.000169	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALB—type 1 diabetes mellitus	5.36e-05	0.00016	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NOS3—type 1 diabetes mellitus	5.13e-05	0.000153	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—type 1 diabetes mellitus	4.37e-05	0.000131	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—INS—type 1 diabetes mellitus	4.15e-05	0.000124	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—type 1 diabetes mellitus	3.97e-05	0.000119	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALB—type 1 diabetes mellitus	3.8e-05	0.000114	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NOS3—type 1 diabetes mellitus	3.64e-05	0.000109	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—type 1 diabetes mellitus	3.05e-05	9.13e-05	CbGpPWpGaD
